MRI Biomarkers Identify Histologic Improvement in MASH
Two MRI-derived non-invasive tests predict histologic improvement in patients with metabolic dysfunction-associated steatohepatitis.
Read More
MASH
Treating MASH in Patients With HIV
MASH exerts sex differences in those with HIV, according a recent study focused on sex-based differences in trends of MASH with liver fibrosis.
Read More
In MASH, Research Limited on Cardiac Risk After Liver Transplant
Less is known about cardiac abnormalities in metabolic dysfunction-associated steatohepatitis versus metabolic dysfunction-associated steatotic liver disease.
Read More
Multiple Factors Drive MASH Progression in MASH + Diabetes
Among patients with MASH and Type 2 diabetes, MASH progression is accelerated by adipose tissue and muscle insulin resistance.
Read More
Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis
MASH’s economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of cirrhosis.
Read More
HIIT + Energy Reduction Improves Liver Health in MASH
A combined intervention focusing on energy intake and interval training decreased body weight, fat mass, and liver injury in patients with MASH.
Read More
Study Identifies Genes in NASH-HCC Transformation
A study identified five genes— ME1, TP53I3, SOCS2, GADD45G, and CYP7A1— related to progression from non-alcoholic steatohepatitis to hepatocellular carcinoma.
Read More
Study Reveals MASLD, MetALD Responsible for One-Third of ICU Cirrhosis Cases
MASLD-related and MetALD-related cirrhosis is responsible for one-third of cirrhosis cases seen in the intensive care unit, according to a recent study.
Read More
New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease
A new classification links MASLD and ALD, based on metabolic dysfunction and alcohol use, with a significant risk of developing chronic kidney disease.
Read More
Study Identifies Most Accurate Noninvasive Method for Diagnosing MASH
A recent study compared the predictive performance of three imaging models in order to determine the most accurate noninvasive method for diagnosing MASH.
Read More
FIB-4 Scores Linked to Clinical & Economic Burden
High FIB-4 scores were linked to significantly greater healthcare resource utilization and costs among patients with MASH/NASH.
Read More
Evaluating Probiotics in Early MASH
A recent clinical trial showed that probiotic supplementation in patients with early-stage NASH/MASH did not significantly improve liver or clinical parameters.
Read More
Novel Biomarkers May Distinguish MASH From MASLD
A unique set of cytokine and chemokine markers could serve as biomarkers to differentiate non-alcoholic steatohepatitis from non-alcoholic fatty liver disease.
Read More
Exercise Improves Liver Biomarkers
Study findings suggest that exercise can mitigate liver fibrosis markers effectively, highlighting its role as a weight-neutral intervention supported by accessible biomarkers for widespread clinical use.
Read More
Cardiovascular Disease in MASH vs. Other Liver Diseases
The following is a summary of “Cardiovascular disease in patients with metabolic...
Read More